Accessibility optionsResponsibility
We are determined to help as many people as possible
in a way that is rigorous and collaborative.
Our commitment to Open Science
We are fully committed to Open Science. We will publish the results from all our trials and we support the publication of all results from independent studies that use our proprietary formulation of synthetic psilocybin, COMP360. Read more about our approach here
Our actions
Learn more about our rigorous and collaborative approach to research
-
Our Centres of Excellence
In January 2021, we established our first Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care.
-
Our Discovery Center
Our Discovery Center focuses on developing optimized psychedelic and related compounds targeting the 5-HT2A receptor.
-
Investigator-initiated studies
We have provided support, training and funding for the investigator-initiated study using our COMP360 psilocybin therapy in cancer patients with depression at The Aquilino Cancer Center.
-
Global research partnerships
We work with the Psychiatry Consortium, an international collaboration to accelerate drug discovery and development in areas of urgent, unmet medical need.
-
Physician insights
COMPASS recently conducted a survey with Sermo, a global leader in physician insights, to discover how psychiatrists view the potential future role of psilocybin therapy in treating mental health illnesses, such as treatment-resistant depression.
-
Animal welfare
As part of our commitment to animal welfare, we have joined the Concordat on Openness on Animal Research in the UK.